Multithread effectively and personalize outreach to convert deals faster
Elevate social presence and drive business growth from social media
Identify and prioritize high-intent leads, and improve sales effectiveness
Find and connect with ICP attendees, and improve event outcomes
David Moatazedi is a distinguished leader in the global medical aesthetics industry, currently serving as the President and Chief Executive Officer of Evolus. With nearly two decades of experience, he has a proven track record of building and leading high-performing teams and successfully launching and scaling iconic brands. Before joining Evolus in 2018, he spent over 13 years at Allergan in various executive roles, most notably as Senior Vice President of U.S. Medical Aesthetics. During his tenure, he was instrumental in managing and growing a multi-billion dollar portfolio that included world-renowned products like BOTOX® Cosmetic, JUVÉDERM®, and KYBELLA®. At Evolus, he is leading the charge to disrupt the market with Jeuveau®, the company's flagship neurotoxin, focusing on innovation and a modern approach to medical aesthetics. He holds an MBA from the University of Southern California Marshall School of Business.
David Moatazedi's work history includes a series of influential roles in various companies. Here is a detailed list of his professional journey:
As President and CEO since 2018, David has successfully guided Evolus through its commercial launch of Jeuveau®, establishing the company as a significant 'challenger brand' in the competitive aesthetics market and steering it towards consistent revenue growth and international expansion.
During his 13-year tenure at Allergan, he was a key commercial leader for the U.S. Medical Aesthetics division, directly overseeing the growth and market dominance of a portfolio worth over $2.5 billion, including blockbuster brands BOTOX® Cosmetic and the JUVÉDERM® collection of fillers.
Orchestrated the highly successful U.S. launch and commercialization of Jeuveau®, effectively positioning it as a modern alternative neurotoxin. Under his leadership, the product has rapidly captured significant market share from established competitors.
Pepperdine University, The George L. Graziadio School of Business and Management - Year 2003
California State University-Long Beach - Year 1995
Highperformr Signals uncover buying intent and give you clear insights to target the right people at the right time — helping your sales, marketing, and GTM teams close more deals, faster.
Evolus is a performance beauty company with a customer-centric approach focused on delivering products in the medical aesthetics market. Its primary product, Jeuveau® (prabotulinumtoxinA-xvfs), is a neurotoxin approved by the FDA for the temporary improvement in the appearance of moderate to severe glabellar lines, commonly known as frown lines, in adults. The company aims to be a leading choice for both medical professionals and their patients seeking aesthetic treatments.
Get verified emails, phone numbers, and LinkedIn profile details
Discover contacts with similar roles, seniority, or companies
Uncover insights like skills, work history, social links, and more
Explore contacts in-depth — from verified emails and phone numbers to LinkedIn activity, job changes, and more — all in one powerful view.
Highperformr AI helps you surface the right people and enrich your CRM with live, accurate contact insights so your teams can connect faster and close smarter.
Thousands of contacts — including decision-makers, influencers, and ICP matches — are just a search away.
Thousands of companies, including, are just a search away.